Take a closer look at the latest in vitro strategies helping researchers make better decisions around low clearance compounds in drug discovery.
In this free on-demand session, a panel of experienced scientists and industry professionals will break down the challenges of low intrinsic clearance and share how today’s low clearance assays, in vitro models, and predictive tools can make a difference.
You’ll get a clear scientific presentation followed by an open, interactive panel discussion – with practical insights, real case studies, and proven methods drawn from real-world drug development work.
What you’ll learn
Attendees will walk away with a clearer understanding of:
- How to optimize in vitro assay methods for low clearance compounds
- New technologies that are making it easier to analyze low turnover compounds
- When and how to use calibrated assay models strategically in early discovery
- Real-world examples and case studies that show how to turn data into better decisions
Why this matters
Low clearance compounds can be tough to work with in early drug development, often posing analytical challenges that, if not addressed early, may lead to setbacks later on. Without reliable in vitro models, there's a greater risk of unexpected issues or pushing forward with candidates that won’t succeed.
This webinar takes a look at the latest scientific approaches and best practices to tackle these hurdles, offering practical insights and guidance from leading experts in the field.
About the speakers
- Carl Petersson – Scientific Director at Merck Healthcare KGaA
- Katherine Fenner – in vitro DMPK Laboratory Head at Pharmaron
- Moderated by Chris Bode – VP of Scientific Affairs at Pharmaron